Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
Meanwhile, AstraZeneca and Daiichi Sankyo noted that results from the NeoCOAST-2 Phase II platform trial evaluating Imfinzi (durvalumab) in multiple novel combinations, before and after surgery, in ...
Some results have been hidden because they may be inaccessible to you